ArticleVirology2008
Inhibition of cellular entry of lymphocytic choriomeningitis virus by amphipathic DNA polymers.
Article in Virology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 44 citations in OpenAlex.
- Sulfated glycosaminoglycans inhibit LCMV entry and modulate antiviral immunity and pathology.EMBO molecular medicine · 2026Article
- Article
- Is There a Role for Immunoregulatory and Antiviral Oligonucleotides Acting in the Extracellular Space? A Review and Hypothesis.International journal of molecular sciences · 2022Review
- Oligonucleotide-Based Therapies for Chronic HBV Infection: A Primer on Biochemistry, Mechanisms and Antiviral Effects.Viruses · 2022Review
- Antiviral Polymers: A Review.Polymers · 2022Review
- Combination of Novel Therapies for HDV.Viruses · 2022Review
- Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants.PLoS pathogens · 2021Article
- Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform.Viruses · 2021Article
- Hepatitis D infection: from initial discovery to current investigational therapies.Gastroenterology report · 2019Article
- Anti-Niemann Pick C1 Single-Stranded Oligonucleotides with Locked Nucleic Acids Potently Reduce Ebola Virus Infection In Vitro.Molecular therapy. Nucleic acids · 2019Article
- Pathogenesis of and New Therapies for Hepatitis D.Gastroenterology · 2019Review
- Hemorrhagic Fever-Causing Arenaviruses: Lethal Pathogens and Potent Immune Suppressors.Frontiers in immunology · 2019Review
- Nucleic Acid Polymers Are Active against Hepatitis Delta Virus InfectionJournal of virology · 2018Article
- Inhibition of hepatitis B viral entry by nucleic acid polymers in HepaRG cells and primary human hepatocytes.PloS one · 2017Article
- Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection.PloS one · 2015Article
- Oligonucleotides designed to inhibit TLR9 block Herpes simplex virus type 1 infection at multiple steps.Antiviral research · 2014Article
- Emerging antivirals for the treatment of hepatitis B.World journal of gastroenterology · 2014Review
- Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo.Antimicrobial agents and chemotherapy · 2013Article
- Nucleic acid polymers inhibit duck hepatitis B virus infection in vitro.Antimicrobial agents and chemotherapy · 2013Article
- Targeting virulence mechanisms for the prevention and therapy of arenaviral hemorrhagic fever.Antiviral research · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
Abstract
The prototypic arenavirus lymphocytic choriomeningitis virus (LCMV) represents a powerful experimental model for the study of the basic virology and pathogenesis of arenaviruses. In the present study, we used the LCMV model to evaluate the anti-viral potential of phosphorothioate oligonucleotides against arenaviruses. Our findings indicate that amphipathic DNA polymers (APs) are potent inhibitors of infection with a series of LCMV isolates with IC(50) in the low nanomolar range. APs target the surface glycoprotein (GP) of LCMV and block viral entry and cell-cell propagation of the virus, without affecting later steps in replication or release of progeny virus from infected cells. The anti-viral action of APs is sequence-independent but is critically dependent on their size and hydrophobicity. Mechanistically, we provide evidence that APs disrupt the interaction between LCMVGP and its cellular receptor, alpha-dystroglycan. Exposure of LCMV to APs does not affect the stability of the GP virion spike and has no effect on the conformation of a neutralizing antibody epitope, suggesting rather subtle changes in the conformation and/or conformational dynamics of the viral GP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.